A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose
(MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of
[177Lu]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care
treatment options.
[177Lu]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose
mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.